A Phase 2 Study of Cis‐platinum in Patients with Recurrent Bladder Carcinoma

• DOI: 10.1111/j.1464-410x.1981.tb03227.x
• Publication Date: 2008-11-21T21:29:30Z
• Authors: Grant B. Williams...; R. T. D. OLIVER; E. S. NEWLANDS; E. WILTSHAW; J. S. MALPAS; E. Wiltshaw; J. S. Malpas; E. Newlands; R. T. D. Oliver; M. Alderson; H. J. G. Bloom; H. T. Ford; W. F. Hendry; R. J. Shearer; P. A. Trott; R. Sandland; H. Whitfield; N. Howard; P. F. Philip; J. Boyd; M. Snell; R. Durrant; G. Fellows; J. C. Smith; P. R. Riddle; G. F. Abercrombie; I. Cede; J. Vinnicombe; A. G. Turner
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

Summary— A series of 27 patients with measurable metastases from primary carcinoma of the bladder received cis‐platinum 50 mg/m2/3‐weekly. Twenty‐six per cent (32% if patients receiving only one injection are excluded) responded for a median of 4 months.